1. Home
  2. EDAP vs PRLD Comparison

EDAP vs PRLD Comparison

Compare EDAP & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDAP
  • PRLD
  • Stock Information
  • Founded
  • EDAP 1979
  • PRLD 2016
  • Country
  • EDAP France
  • PRLD United States
  • Employees
  • EDAP N/A
  • PRLD N/A
  • Industry
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • PRLD Medicinal Chemicals and Botanical Products
  • Sector
  • EDAP Health Care
  • PRLD Health Care
  • Exchange
  • EDAP Nasdaq
  • PRLD Nasdaq
  • Market Cap
  • EDAP 46.7M
  • PRLD 44.0M
  • IPO Year
  • EDAP 1997
  • PRLD 2020
  • Fundamental
  • Price
  • EDAP $2.74
  • PRLD $1.25
  • Analyst Decision
  • EDAP Buy
  • PRLD Strong Buy
  • Analyst Count
  • EDAP 3
  • PRLD 3
  • Target Price
  • EDAP $8.50
  • PRLD $4.00
  • AVG Volume (30 Days)
  • EDAP 179.1K
  • PRLD 219.0K
  • Earning Date
  • EDAP 11-06-2025
  • PRLD 11-05-2025
  • Dividend Yield
  • EDAP N/A
  • PRLD N/A
  • EPS Growth
  • EDAP N/A
  • PRLD N/A
  • EPS
  • EDAP N/A
  • PRLD N/A
  • Revenue
  • EDAP $74,008,221.00
  • PRLD $7,000,000.00
  • Revenue This Year
  • EDAP N/A
  • PRLD N/A
  • Revenue Next Year
  • EDAP N/A
  • PRLD N/A
  • P/E Ratio
  • EDAP N/A
  • PRLD N/A
  • Revenue Growth
  • EDAP 1.56
  • PRLD N/A
  • 52 Week Low
  • EDAP $1.21
  • PRLD $0.61
  • 52 Week High
  • EDAP $3.29
  • PRLD $5.53
  • Technical
  • Relative Strength Index (RSI)
  • EDAP 78.55
  • PRLD 60.92
  • Support Level
  • EDAP $2.33
  • PRLD $1.10
  • Resistance Level
  • EDAP $3.05
  • PRLD $1.26
  • Average True Range (ATR)
  • EDAP 0.26
  • PRLD 0.15
  • MACD
  • EDAP 0.13
  • PRLD 0.00
  • Stochastic Oscillator
  • EDAP 82.29
  • PRLD 81.13

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Share on Social Networks: